Guardant Health (NASDAQ:GH) PT Lowered to $30.00

Guardant Health (NASDAQ:GH - Free Report) had its target price cut by Canaccord Genuity Group from $45.00 to $30.00 in a research report released on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

GH has been the topic of a number of other research reports. Guggenheim restated a neutral rating on shares of Guardant Health in a research report on Friday, April 5th. Craig Hallum started coverage on Guardant Health in a research note on Wednesday, April 24th. They issued a buy rating and a $28.00 price objective for the company. Piper Sandler cut their target price on Guardant Health from $40.00 to $30.00 and set an overweight rating on the stock in a research report on Monday, February 26th. JPMorgan Chase & Co. lowered their price target on Guardant Health from $60.00 to $45.00 and set an overweight rating for the company in a research report on Friday, February 23rd. Finally, The Goldman Sachs Group cut their price objective on shares of Guardant Health from $32.00 to $28.00 and set a buy rating on the stock in a research report on Monday, April 15th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $37.91.

Guardant Health Trading Up 4.8 %

Shares of NASDAQ GH traded up $0.84 during midday trading on Monday, hitting $18.19. 1,578,164 shares of the company traded hands, compared to its average volume of 1,873,950. The stock has a 50-day moving average price of $18.74 and a 200 day moving average price of $22.80. The company has a debt-to-equity ratio of 7.18, a quick ratio of 6.24 and a current ratio of 6.54. The firm has a market cap of $2.21 billion, a P/E ratio of -4.25 and a beta of 0.87. Guardant Health has a 12-month low of $15.81 and a 12-month high of $41.06.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.65). Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. The business had revenue of $155.05 million for the quarter, compared to analysts' expectations of $151.71 million. As a group, analysts expect that Guardant Health will post -3.49 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Kumud Kalia acquired 2,187 shares of the business's stock in a transaction dated Monday, March 18th. The shares were purchased at an average price of $17.82 per share, for a total transaction of $38,972.34. Following the completion of the acquisition, the insider now directly owns 12,722 shares in the company, valued at approximately $226,706.04. The transaction was disclosed in a document filed with the SEC, which is available through this link. 6.20% of the stock is owned by company insiders.

Institutional Trading of Guardant Health

Several institutional investors and hedge funds have recently bought and sold shares of the business. CWM LLC increased its holdings in shares of Guardant Health by 137.1% during the 3rd quarter. CWM LLC now owns 984 shares of the company's stock valued at $29,000 after purchasing an additional 569 shares in the last quarter. BluePath Capital Management LLC purchased a new position in Guardant Health in the third quarter valued at $35,000. Headlands Technologies LLC boosted its stake in shares of Guardant Health by 362.3% during the 4th quarter. Headlands Technologies LLC now owns 2,353 shares of the company's stock worth $64,000 after acquiring an additional 1,844 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of Guardant Health by 29.4% during the 4th quarter. Van ECK Associates Corp now owns 2,702 shares of the company's stock worth $73,000 after acquiring an additional 614 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its position in shares of Guardant Health by 26.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,450 shares of the company's stock valued at $102,000 after acquiring an additional 713 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.